Management of tenosynovial giant cell tumour of the foot and ankle

Geert Spierenburg(Leiden University Medical Center), C. L. M. H. Gibbons(Nuffield Orthopaedic Centre), Michiel A. J. van de Sande(Leiden University Medical Center), Sarah Pratap(Churchill Hospital), M.J.L. Mastboom(Leiden University Medical Center), L. van der Heijden(Leiden University Medical Center), Sarah Lancaster(Nuffield Orthopaedic Centre), Hans Gelderblom(Leiden University Medical Center)
The Bone & Joint Journal
April 1, 2021
10.1302/0301-620x.103b4.bjj-2020-1582.r1
Cited by 22

Related Papers

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k